Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition and application thereof

A composition and drug technology, applied in the field of medicine, can solve problems such as undiscovered applications, achieve the effects of preventing and treating infections, reducing treatment costs, and reducing dosage

Inactive Publication Date: 2018-08-14
GUIZHOU MEDICAL UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The above studies all show that fusaric acid itself has inhibitory effects on many different fungi, bacteria or viruses, but no application involving fusaric acid or fusaric acid-type compounds in combination with one or more antibiotics has been found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition and application thereof
  • Pharmaceutical composition and application thereof
  • Pharmaceutical composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] In vitro antibacterial activity of fusaric acid or fusaric acid-type compounds (sodium fusaric acid, ethyl fusaric acid) alone against clinically resistant Escherichia coli, Klebsiella pneumoniae, Staphylococcus epidermidis and Enterococcus faecium Determination and comparison of antibacterial activity.

[0057] 1 Materials and methods

[0058] 1.1 Clinical drug-resistant strains

[0059] Clinical multidrug-resistant strains of Escherichia coli (bacteria number: 20151027024), Klebsiella pneumoniae (bacteria number: 20151025062), Staphylococcus epidermidis (bacteria number: 20151026055) and Enterococcus faecium (bacteria number: 20151023070) were selected from Guizhou Donated by the Laboratory Department of the Affiliated Hospital of Medical University, all of them are clinically isolated multi-drug resistant strains.

[0060] 1.2 Drugs and reagents

[0061] Ampicillin is a product of Bailingwei Company, with a purity of ≥98%. The fusaric acid is isolated and prepare...

Embodiment 2

[0071] In vitro antibacterial activity assay and comparison of antibacterial activity of a fusaric acid / ciprofloxacin composition against clinically resistant Escherichia coli, Klebsiella pneumoniae, Staphylococcus epidermidis, and Enterococcus faecium.

[0072] 1 Materials and methods

[0073] 1.1 Clinical drug-resistant strains

[0074] Clinical multidrug-resistant strains of Escherichia coli (bacteria number: 20151027024), Klebsiella pneumoniae (bacteria number: 20151025062), Staphylococcus epidermidis (bacteria number: 20151026055) and Enterococcus faecium (bacteria number: 20151023070) were selected from Guizhou Donated by the Laboratory Department of the Affiliated Hospital of Medical University, all of them are clinically isolated multi-drug resistant strains.

[0075] 1.2 Drugs and reagents

[0076] Ciprofloxacin, levofloxacin, ceftriaxone, ampicillin, and tetracycline are products of Bailingwei Company, with a purity of ≥98%. The fusaric acid is isolated and prepar...

Embodiment 3

[0090] In vitro antibacterial activity assay and comparison of antibacterial activity of a fusaric acid / levofloxacin composition against clinically resistant Escherichia coli, Klebsiella pneumoniae, Staphylococcus epidermidis, and Enterococcus faecium.

[0091] The antibacterial activity of the fusaric acid / levofloxacin composition against clinical drug-resistant Escherichia coli, Klebsiella pneumoniae, Staphylococcus epidermidis and Enterococcus faecium was determined according to the experimental method of Example 2, and the results are shown in Table 3.

[0092] Table 3 Antibacterial activity of fusaric acid combined with levofloxacin against drug-resistant bacteria

[0093] Table 3 Fusaric acid combined with levofloxacin antibacterial activity of resistant bacteria

[0094]

[0095]

[0096] The above experimental results show that the combination of fusaric acid / levofloxacin has stronger antibacterial effect on clinical multidrug-resistant Escherichia coli, Klebsiel...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition and an application thereof, which belongs to the technical field of a medicine. The pharmaceutical composition comprises fusaric acid or a fusaricacid compound and one of quinolone, beta-lactams and / or tetracycline antibiotic or a plurality of antibiotics with a mass ratio of 1: 500-128:1, and is used for preparing a medicine for treating and preventing diseases due to drug-resistant bacteria. The composition can effectively solve the drug resistance problem of bacteria on a plurality of antibiotics, the components have synergistic interaction effect, the usage of antibiosis drugs in clinical application of the antibiosis drugs is reduced, side effect and the treatment cost generated due to antibiotic can be correspondingly reduced, andthe sensitivity of the antibiosis drugs can be reduced.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a pharmaceutical composition and its application. Background technique [0002] At present, the drug resistance of common pathogenic bacteria in hospital-acquired patients, such as Escherichia coli, Klebsiella pneumoniae, Staphylococcus epidermidis and Enterococcus faecium, is becoming more and more serious. However, with the inappropriate use of broad-spectrum antibiotics, the problem of drug resistance caused by antibiotic abuse in my country is particularly prominent (Glover M, Moreira C G, Sperandio V, et al.Recurrenturinary tract infections in healthy and nonpregnant women[J].UrologicalScience,2014 , 25(1):1-8.). They are not only highly resistant to a single antibiotic, but also often resistant to multiple antibiotics at the same time, making clinical treatment very difficult. At present, antibiotics (such as quinolones, β-lactams, etc.) are still the first-line treatment...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/44A61K31/496A61K31/5383A61K31/546A61K31/43A61K31/65A61P31/04
CPCA61K31/44A61K31/43A61K31/496A61K31/5383A61K31/546A61K31/65A61P31/04A61K2300/00
Inventor 徐国波刘俊雷丹丹张青艳肖耀华廖尚高周孟何迅张婷婷李靖李勇军
Owner GUIZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com